查看文章

Objective To evaluate the 12-month total direct costs (medical and nonmedical) of delivering subcutaneous depot medroxyprogesterone acetate (DMPA-SC) under three strategies—facility-based administration, community-based administration and self-injection—compared to the costs of delivering intramuscular DMPA (DMPA-IM) via facility-and community-based administration. Study design We conducted four cross-sectional microcosting studies in three countries from December 2015 to January 2017. We estimated direct medical costs (ie, costs to health systems) using primary data collected from 95 health facilities on the resources used for injectable contraceptive service delivery. For self-injection, we included both costs of the actual research intervention and adjusted programmatic costs reflecting a lower-cost training aid. Direct nonmedical costs (ie, client travel and time costs) came from client interviews …